Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

nificant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH; - No statistically significant impact on quality of life or erectile function; and - Intramuscular 15 mg + 15 mg was the most effective regimen in this study. About Ozarelix and Partnerships

Ozarelix is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist administered as a depot formulation for the treatment of benign and malign hormone-dependent diseases. It is currently in Phase 2b clinical trials for both BPH and prostate cancer.

In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America and India, while AEterna Zentaris retains exclusive rights to the rest of the world. Spectrum will also receive 50% of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan.

Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to Nippon Kayaku, a key player in the Japanese oncology market.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Enlargement of the prostate is controlled by testosterone. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options are inconvenient, leading to ineffective compliance and are only effective in roughly half of the patients treated. According to Decision Resource, in 2004, the total prevalence cases
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., ... is pleased to announce that its animal research ... for the Assessment and Accreditation of Laboratory Animal ... of animals in science worldwide through voluntary accreditation ... for animal care and use in 38 countries. ...
(Date:7/14/2014)... , July 14, 2014  Today, ATS Labs, ... that it acquired the assets of MicroTest Labs, Inc. ... acquisition of MTL is the first step in the ... laboratory services platform to support the medical device and ... as Accuratus Lab Services , a name that ...
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8
(Date:7/14/2014)... (PRWEB) July 14, 2014 Jordan Valley ... of a new comprehensive cancer center set to open ... will be the only hospital west of I-15 in ... cancer services , Additionally, Jordan Valley Medical Center has ... and cancer treatment planning systems for radiation therapy, radiosurgery ...
(Date:7/14/2014)... 14, 2014 The report “Intelligent ... [Physical Security, Life Safety, Facility Management], IT Technologies ... & Analysis (2014 - 2019)” defines and segments ... in-depth analysis and forecasting of revenues. The report ... restraints and opportunities impacting it, along with the ...
(Date:7/14/2014)... 2014 BCC Research ( http://www.bccresearch.com ... BIOLOGY: GLOBAL MARKETS , the global synthetic biology ... billion in 2018, with a five-year compound annual ... for the fastest growing segment, with anticipated $9.7 ... products in the pharmaceutical/diagnostics, chemical, energy, and agricultural ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
(Date:7/14/2014)... Amy Norton HealthDay Reporter ... adults who enjoy mentally stimulating games may have bigger brains ... The study looked at the connection between playing games ... for adults in their 50s and 60s. Researchers found ... day performed better on tests of memory and other mental ...
Breaking Medicine News(10 mins):Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... Two animal studies published in the journal Carcinogenesis show that ... physically active mice// that had a round the clock access ... other study found that exercise and a restricted diet had ... in the animals. ,The first study exposed mice ...
... new finding and revelation comes in the form of health ... the heart. ,The petition proposed as a model qualified health// ... (150 mL) of green tea as a source of catechins ... disease. FDA has determined that the evidence is supportive, but ...
... concern over the high maternal mortality rate in Madhya ... groups to help check the menace//. ,With 13,000 ... maternal mortality rate of the state is one of ... women's meet at the missionary-run Asha Niketan Welfare Centre ...
... which stated that doctors can give drugs to end the ... the upper house of British parliament//. The assisted dying bill ... stated that doctors can prescribe lethal drugs to patients who ... live. These drugs can be administered by the patients to ...
... have become so inadequate that students are becoming increasingly ... vital organs with each other. ,Senior doctors ... medical students are not being properly trained. ... properly trained in anatomy. According to them teaching hours ...
... percentages of undernourished children in the world, the situation ... report released Thursday//. ,"India's Integrated Child Development Services ... current malnutrition crisis," states the report "India's Undernourished Children: ... of underweight children in India is among the highest ...
Cached Medicine News:Health News:Green tea’s health claims questioned: FD 2Health News:Green tea’s health claims questioned: FD 3Health News:Malnutrition Crisis On Rise In India: World Bank 2
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: